These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 9168821)

  • 21. Role of activated protein C in facilitating basement membrane invasion by tumor cells.
    Kobayashi H; Moniwa N; Gotoh J; Sugimura M; Terao T
    Cancer Res; 1994 Jan; 54(1):261-7. PubMed ID: 8261450
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Haemostatic factors occupy new territory: the role of the urokinase receptor system and kininogen in inflammation.
    Chavakis T; Kanse SM; May AE; Preissner KT
    Biochem Soc Trans; 2002 Apr; 30(2):168-73. PubMed ID: 12023845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn.
    Schroeck F; Arroyo de Prada N; Sperl S; Schmitt M; Viktor M
    Biol Chem; 2002; 383(7-8):1143-9. PubMed ID: 12437099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of urokinase-type plasminogen activator receptor is correlated with metastases of lingual squamous cell carcinoma.
    Wang J; Guo F; Wei H; Dong J; Wu J
    Br J Oral Maxillofac Surg; 2006 Dec; 44(6):515-9. PubMed ID: 16356605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular and functional interdependence of the urokinase-type plasminogen activator system with integrins.
    Reuning U; Magdolen V; Hapke S; Schmitt M
    Biol Chem; 2003 Aug; 384(8):1119-31. PubMed ID: 12974381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasminogen activator mediated degradation of subendothelial extracellular matrix by human squamous carcinoma cell lines.
    Niedbala MJ; Sartorelli AC
    Cancer Commun; 1990; 2(5):189-99. PubMed ID: 2142433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Plasminogen activator-inhibitor 1: biochemical, structural and functional studies].
    Declerck P
    Verh K Acad Geneeskd Belg; 1993; 55(5):457-73. PubMed ID: 8128782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-1alpha enhances the aggressive behavior of pancreatic cancer cells by regulating the alpha6beta1-integrin and urokinase plasminogen activator receptor expression.
    Sawai H; Okada Y; Funahashi H; Matsuo Y; Takahashi H; Takeyama H; Manabe T
    BMC Cell Biol; 2006 Feb; 7():8. PubMed ID: 16504015
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration.
    Zhou A; Huntington JA; Pannu NS; Carrell RW; Read RJ
    Nat Struct Biol; 2003 Jul; 10(7):541-4. PubMed ID: 12808446
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
    Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
    FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin.
    Waltz DA; Natkin LR; Fujita RM; Wei Y; Chapman HA
    J Clin Invest; 1997 Jul; 100(1):58-67. PubMed ID: 9202057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin.
    Stefansson S; Lawrence DA
    Nature; 1996 Oct; 383(6599):441-3. PubMed ID: 8837777
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins.
    Czekay RP; Aertgeerts K; Curriden SA; Loskutoff DJ
    J Cell Biol; 2003 Mar; 160(5):781-91. PubMed ID: 12615913
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Both u-PA inhibition and vitronectin binding by plasminogen activator inhibitor 1 regulate HT1080 fibrosarcoma cell metastasis.
    Praus M; Collen D; Gerard RD
    Int J Cancer; 2002 Dec; 102(6):584-91. PubMed ID: 12447999
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations.
    Chazaud B; Ricoux R; Christov C; Plonquet A; Gherardi RK; Barlovatz-Meimon G
    Am J Pathol; 2002 Jan; 160(1):237-46. PubMed ID: 11786417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss of the metastatic phenotype by a human epidermoid carcinoma cell line, HEp-3, is accompanied by increased expression of tissue inhibitor of metalloproteinase 2.
    Testa JE
    Cancer Res; 1992 Oct; 52(20):5597-603. PubMed ID: 1327511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. RNA aptamers as conformational probes and regulatory agents for plasminogen activator inhibitor-1.
    Madsen JB; Dupont DM; Andersen TB; Nielsen AF; Sang L; Brix DM; Jensen JK; Broos T; Hendrickx ML; Christensen A; Kjems J; Andreasen PA
    Biochemistry; 2010 May; 49(19):4103-15. PubMed ID: 20387790
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness.
    Blasi F
    Bioessays; 1993 Feb; 15(2):105-11. PubMed ID: 8385942
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibody and synthetic peptide inhibitors of human tumor cell migration.
    Yamada KM; Kennedy DW; Yamada SS; Gralnick H; Chen WT; Akiyama SK
    Cancer Res; 1990 Aug; 50(15):4485-96. PubMed ID: 2369727
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer.
    Lobov S; Ranson M
    Cancer Lett; 2011 Apr; 303(2):118-27. PubMed ID: 21316840
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.